MARKET

RGNX

RGNX

Regenxbio
NASDAQ

Real-time Quotes | Nasdaq Last Sale

42.32
-1.16
-2.67%
Closed 16:00 09/24 EDT
OPEN
42.99
PREV CLOSE
43.48
HIGH
43.49
LOW
42.22
VOLUME
249.65K
TURNOVER
--
52 WEEK HIGH
50.26
52 WEEK LOW
26.40
MARKET CAP
1.80B
P/E (TTM)
-11.8730
1D
5D
1M
3M
1Y
5Y
Pharma Stock Roundup: ABBV's Deal With RGNX, LLY COVID Drug's Government Order Win
Zacks.com · 09/17 11:40
Insider Sell: Regenxbio
MT Newswires · 09/15 16:40
Looking Into Regenxbio's Return On Capital Employed
Regenxbio (NASDAQ:RGNX) brought in sales totaling $22.04 million during Q2 according to data provided by Benzinga Pro. However, earnings decreased 18.58%, resulting in a loss of $52.23 million.
Benzinga · 09/15 16:02
Regenxbio Inc (RGNX) President and CEO Kenneth T. Mills Sold $1.7 million of Shares
GuruFocus News · 09/15 09:51
REGENXBIO (RGNX) Stock Up on Collaboration Deal With AbbVie
REGENXBIO (RGNX) enters into a strategic partnership with AbbVie to co-develop and commercialize RGX-314, a potential gene therapy for retinal indications. Resultantly, REGENXBIO's share price surges.
Zacks · 09/14 14:55
AbbVie (ABBV) to Co-Develop Regenxbio Eye Disease Gene Therapy
AbbVie (ABBV) is set to co-develop Regenexbio's investigational gene therapy for chronic retinal diseases like wet age-related macular degeneration.
Zacks · 09/14 14:45
5 Gene Therapy Stocks Back in Focus on AbbVie/Regenxbio Deal
The promising gene therapy approach is being evaluated for varied diseases, such as hemophilia, Duchenne muscular dystrophy (DMD), Parkinson's disease, eye disease, and cancer among others
Zacks · 09/14 14:24
SVB Leerink Adjusts Price Target for Regenxbio to $44 From $40, Maintains Market Perform Rating
MT Newswires · 09/14 12:37
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of RGNX. Analyze the recent business situations of Regenxbio through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average RGNX stock price target is 65.13 with a high estimate of 100.00 and a low estimate of 44.00.
EPS
Institutional Holdings
Institutions: 248
Institutional Holdings: 35.40M
% Owned: 83.09%
Shares Outstanding: 42.60M
TypeInstitutionsShares
Increased
70
2.76M
New
12
156.82K
Decreased
52
1.79M
Sold Out
25
462.40K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.13%
Pharmaceuticals & Medical Research
-1.02%
Key Executives
Chairman/Director
Allan Fox
President/Chief Executive Officer/Director
Kenneth Mills
Chief Financial Officer/Senior Vice President
Vittal Vasista
Chief Operating Officer/Senior Vice President
Curran Simpson
Senior Vice President/Chief Scientific Officer
Olivier Danos
Senior Vice President
Patrick Christmas
Senior Vice President
Steve Pakola
Lead Director/Independent Director
A. N. Karabelas
Director
Jean Bennett
Director
George Migausky
Independent Director
Daniel Abdun-Nabi
Independent Director
Alexandra Glucksmann
Independent Director
David Stump
Independent Director
Daniel Tasse
No Data
About RGNX
REGENXBIO Inc. is a clinical-stage biotechnology company. The Company's gene therapy product candidates are designed to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. The Company develops products candidates across the therapeutic areas of metabolic, neurodegenerative and retinal diseases. Its product candidate, RGX-314, is meant for the treatment of wet age-related macular degeneration (wet AMD). Its product candidate, RGX-501, is meant for the treatment of homozygous familial hypercholesterolemia (HoFH). It is also developing product candidates, such as RGX-111 and RGX-121, to address the neurological symptoms of two severe genetic lysosomal storage diseases, Mucopolysaccharidosis Type I (MPS I) and Mucopolysaccharidosis Type II (MPS II), respectively. Its product candidates utilize viral vectors from its gene delivery platform, NAV Technology Platform.

Webull offers kinds of Regenxbio Inc stock information, including NASDAQ:RGNX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RGNX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading RGNX stock methods without spending real money on the virtual paper trading platform.